Lopinavir News and Research

RSS

Phase III STARTMRK clinical study on ISENTRESS in comparison to efavirenz

ISENTRESS , an integrase inhibitor from Merck & Co., Inc., was studied in comparison to efavirenz in maintaining viral load suppression to undetectable levels (less than 50 copies/mL) and at improving CD4 cell counts in previously untreated (treatment-naïve) HIV-1-infected patients through 96 weeks in a Phase III study called STARTMRK.

14 Sep 2009

Tobira Therapeutics presents TBR-652 in vitro data for treating HIV at the 49th ICAAC

Tobira Therapeutics Inc., a clinical stage biotechnology company committed to research and product discovery for the treatment of life-threatening and life-altering infectious diseases, today announced results from an in vitro study evaluating TBR-652 in combination with lopinavir (LPV), darunavir (DRV), atazanavir (ATV), tenofovir (TDF), etravirine (ETV), and raltegravir (RAL) using the infectious replicative assay deCIPhR.

14 Sep 2009

Early retroviral use best for AIDS patients with serious complications

HIV-positive patients who don't seek medical attention until they have a serious AIDS-related condition can reduce their risk of death or other complications by half if they get antiretroviral treatment early on, according to a new multicenter trial led by researchers at the Stanford University School of Medicine.

17 May 2009

Early use of antiretroviral treatment improves survival rate of HIV patients

A clinical study, led by researchers from University College Dublin, Ireland, and Stanford University, California, USA, with international collaborators, demonstrates that mortality rates of HIV patients can be almost halved when early antiretroviral (ARV) therapy is added to the treatment of AIDS-related opportunistic infections (OIs) such as pneumonia, meningitis or other serious bacterial infections.

17 May 2009

Mylan's Matrix receives WHO approval for generic Lopinavir/Ritonavir tablets

Mylan Inc. has announced that Matrix Laboratories Limited, its India-based subsidiary in which it holds a 71.5% controlling interest, received the first and only World Health Organization (WHO) approval for Lopinavir/Ritonavir Tablets, 200 mg/50 mg. Matrix's version of this product is heat-stable and affordable, making it practical for distribution and use in warm climates.

25 Feb 2009

AIDS advocates tell WHO: Stop harmful single-dose treatment for expectant mothers and infants

As World AIDS Day 2008 approaches, a coalition of hundreds of HIV/AIDS medical care providers and advocates, representing dozens of organizations, today sent a letter to Dr. Margaret Chan, Director General of the World Health Organization (WHO), urging an end to harmful single-dose HIV/AIDS treatment as a recommended treatment for expectant mothers and infants worldwide.

25 Nov 2008

Results out from first phase III randomized clinical trial to study the best time to begin ART in infants

Testing very young babies for HIV and giving antiretroviral therapy (ART) immediately to those found infected with the virus dramatically prevents illness and death, according to a report in the New England Journal of Medicine.

19 Nov 2008

Crestor (rosuvastatin calcium) shown to significantly reduce major cardiovascular events

New data from the JUPITER study demonstrated that Crestor (rosuvastatin calcium) 20 mg significantly reduced major cardiovascular (CV) events (defined in this study as the combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by a dramatic 44% compared to placebo (p<0.001) among men and women with elevated hsCRP but low to normal cholesterol levels.

10 Nov 2008

Gilead initiates phase III trial of Elvitegravir

Gilead Sciences, Inc. has announced that it has begun enrolling patients in a Phase III clinical trial of its investigational antiretroviral agent elvitegravir (GS 9137), a novel oral integrase inhibitor that is being evaluated for the treatment of HIV-1 infection.

22 Jul 2008

Clinton Foundation, UNITAID announce new antiretroviral discounts

The Clinton Foundation HIV/AIDS Initiative and UNITAID on Monday announced that they have negotiated agreements with generic drug companies that will reduce the cost of some antiretroviral drugs and provide new pediatric formulations, the Wall Street Journal reports.

29 Apr 2008

Etravirine reduces HIV viral loads when taken with Prezista

The experimental antiretroviral drug etravirine, made by Johnson & Johnson subsidiary Tibotec Pharmaceuticals, greatly reduces HIV viral loads in people with a history of drug resistance when taken in combination with Tibotec's antiretroviral Prezista, according to two studies published Saturday in the journal The Lancet.

10 Jul 2007

Darunavir-ritonavir shows benefits for patients with HIV

Darunavir-ritonavir should be considered as a treatment option across the range of treatment-experienced patients with HIV infection, conclude Jose Madruga (Centro de Referencia e Treinamento DST/AIDS, Sao Paulao, Brazil) and colleagues in an Article in this week's issue of The Lancet.

8 Jul 2007

WHO welcomes decision by Abbott Labs to reduce price of lopinavir/ritonavir

The World Health Organization (WHO) is committed to work towards universal access, by 2010, to HIV prevention services and to treatment and care for people living with HIV/AIDS.

11 Apr 2007

Abbott agrees with WHO to expand access to lopinavir / ritonavir

Abbott and World Health Organization (WHO) Director-General, Margaret Chan, have agreed on a balanced approach to provide Kaletra/Aluvia (lopinavir/ritonavir) capsules and tablets to more patients in the developing world, while supporting continued long-term biopharmaceutical research and development.

10 Apr 2007

Treatments used for SARS no benefit to victims

Researchers have found, following a systematic review of all studies done on the 2003 SARS epidemic, that none of the treatments used to treat patients appear to have worked.

13 Sep 2006

SARS: Systematic review of treatment effects

The SARS virus set alarm bells ringing across the world when it first appeared in 2002, but now a review of the effectiveness of the treatments used against it has found no evidence that any of them worked.

12 Sep 2006

Antiretroviral drug Lopinavir selectively kills HPV-infected cells in lab tests

The protease inhibitor lopinavir - the primary component of Abbott Laboratories' antiretroviral drug Kaletra - selectively killed the human papillomavirus in laboratory tests, according to a study scheduled to be published next month in the journal Anti-Viral Therapy.

From The University of Manchester 30 Aug 2006

Simpler and less expensive method of controlling the progression of HIV

There might be a simpler and less expensive method of controlling the progression of HIV, according to several preliminary studies presented last Thursday at the XVI International AIDS Conference in Toronto, the Los Angeles Times reports (Chong, Los Angeles Times, 8/18).

20 Aug 2006

Importance of the drug Fuzeon (enfuvirtide) in the management of HIV

New potent combinations make suppression of virus to undetectable levels more achievable for treatment-experienced HIV patients.

20 Oct 2005

HIV/AIDS drugs may also be effective against malaria

Researchers at The Queensland Institute of Medical Research (QIMR) have found that drugs used to treat HIV Aids may also be effective against the biggest killer in the world - malaria.

2 Jun 2005